Multicenter Phase 2 Study of Neoadjuvant Paclitaxel, Estramustine Phosphate, and Carboplatin Plus Androgen Deprivation Before Radiation Therapy in Patients With Unfavorable-Risk Localized Prostate Cancer: Results of Cancer and Leukemia Group B 99811.

The article presents a study which evaluates the safety and feasibility of radiotherapy after paclitaxel, estramustine phosphate and carboplatin (TEC) plus androgen therapy in previously treated prostate cancer patients. It mentions that patients with localized high-risk prostate cancer were treated with four cycles of paclitaxel in a period of 16 weeks. It affirms that the authors concluded that neoadjuvant chemohormonal therapy with TEC followed by high-dose radiation therapy is safe.